Pancreatic Cell News 7.49 December 13, 2016 | |
| |
TOP STORYResearchers have produced artificial beta cells using a straightforward engineering approach. These pancreatic cells can do everything that natural ones do: they measure the glucose concentration in the blood and produce enough insulin to effectively lower the blood sugar level. [Press release from the Swiss Federal Institute of Technology in Zurich discussing online prepublication in Science] Press Release | Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISUsing an obese F2 mouse intercross segregating for type 2 diabetes (T2D), the authors showed that the expression of ~40% of the T2D-associated genes is linked to a broad region on mouse chromosome 2. [PLoS Genet] Full Article Investigators showed that PKC signaling, which is employed by many non-nutrient secretagogues, augments mitochondrial respiration in INS-1E (rat insulinoma cell line clone 1E) and human pancreatic β-cells. [FASEB J] Abstract Economic 3D-Printing Approach for Transplantation of Human Stem Cell-Derived β-Like Cells The authors present a multifaceted transplantation strategy that combines differentiation into stem cell-derived β cells with three-dimensional (3D) printing. [Biofabrication] Abstract | Press Release Researchers determined the effect of siRNA against the collagen specific chaperone, HSP47, which inhibits collagen secretion from activated pancreas stellate cells, and induces their apoptosis, on regeneration of remnant pancreas. [PLoS One] Full Article Glucotoxicity obstructs pancreatic differentiation from adult stem cells. Researchers developed a novel protocol for differentiation of dental pulp stem cells into pancreatic β cells and determined the effect of H2S on glucotoxicity. [Regen Med] Abstract PANCREATIC CANCERPD-L1 Blockade Enhances Response of Pancreatic Ductal Adenocarcinoma to Radiotherapy The authors showed that treatment of KPC and Pan02 murine pancreatic ductal adenocarcinoma cells with radiotherapy and gemcitabine upregulated PD-L1 expression in a JAK/Stat1-dependent manner. [EMBO Mol Med] Abstract | Graphical Abstract ER Stress Protein AGR2 Precedes and Is Involved in the Regulation of Pancreatic Cancer Initiation Researchers analyzed the role of anterior gradient-2 (AGR2) in the earliest stages of pancreatic neoplasia. Immunohistochemical analysis of chronic pancreatitis and peritumoral areas in pancreatic ductal adenocarcinoma tissues showed that AGR2 was present in tubular complexes and early pancreatic intraepithelial neoplasia. [Oncogene] Full Article Scientists reported a new delivery strategy for a G4-decoy oligonucleotide that sequesters MAZ, a transcription factor essential for KRAS transcription. It is based on the use of palmitoyl-oleyl-phosphatidylcholine liposomes functionalized with lipid-modified G4-decoy oligonucleotides and a lipid-modified cell penetrating TAT peptide. The potency of the strategy in pancreatic cancer cells is demonstrated by cell cytometry, confocal microscopy, clonogenic and qRT-PCR assays. [Sci Rep] Full Article Investigators used liquid chromatography-tandem mass spectrometry to assess preassumed modification of the lysine residues of histone proteins in formalin-fixed, paraffin-embedded or fresh-frozen tumor xenografts, derived from the human pancreatic cancer cell line, Capan-1. [Lab Invest] Abstract | |
| |
REVIEWSRole of MiRNAs in the Pathogenesis and Susceptibility of Diabetes Mellitus The authors focus on the role of miRNAs in the pathophysiology of the metabolic disease and diabetes mellitus, the hallmark of which is hyperglycemia caused by defective insulin secretion and/or action. [J Hum Genet] Abstract Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
INDUSTRY NEWSDefymed Enters Partnership with Semma Therapeutics Defymed announces a strategic collaboration with Semma Therapeutics with the goal of developing of an innovative solution for treating type-1 diabetes. The collaboration is aimed at pre-clinical validation of the MAILPAN® bio-artificial pancreas, in combination with stem-cell derived differentiated insulin-secreting cells developed by Semma Therapeutics. [Defymed Inc.] Press Release Kadimastem announced the signing of a memorandum of understanding with Korean company Corestem, for a broad strategic collaboration between the companies. The synergy between the companies will assist in expediting Kadimastem’s entry into international markets and positioning the Kadimastem-Corestem collaboration as a worldwide leader in innovative treatment for severe diseases in general and ALS and diabetes in particular. [Kadimastem] Press Release Novocure presented data from its Phase II pilot PANOVA clinical trial at its research and development day suggesting that Tumor Treating Fields plus first-line chemotherapies nab-paclitaxel and gemcitabine may be tolerable and safe in patients with advanced pancreatic cancer. [Novocure] Press Release The U.S. Food and Drug Administration (FDA) has approved Synjardy® XR tablets for adults with type 2 diabetes. When used along with diet and exercise, SYNJARDY XR is indicated to improve blood sugar in adults with type 2 diabetes when both empagliflozin and metformin can be taken. [Eli Lilly and Company] Press Release NIH Funds Center for Diabetes Translation Research Led by Albert Einstein College of Medicine The National Institutes of Health has awarded researchers at Albert Einstein College of Medicine and Montefiore Health System a five-year, $2.9-million grant to launch a new center, one of only eight in the country, for diabetes translation research. The center—the New York Regional Center for Diabetes Translation Research—also includes faculty from the Icahn School of Medicine at Mt. Sinai and the New York Academy of Medicine and will serve as a collaborative hub for investigators conducting studies on pre-diabetes, diabetes and its complications. [Albert Einstein College of Medicine] Press Release Tyme Technologies, Inc. announced the launch of a Pancreatic Research Program with the Mayo Clinic led by Dr. Martin Fernandez-Zapico. Dr. Martin E. Fernandez-Zapico, Associate Professor of Medicine and Pharmacology at the Mayo Clinic, is an international expert in the field of pancreatic cancer. His work has been seminal for the understanding of mechanisms driving this malignancy and serves as a foundation for multiple National Cancer Institute sponsored clinical trials. [Tyme Technologies, Inc.] Press Release | |
| |
POLICY NEWSUnder 21st Century Cures Legislation, Stem Cell Advocates Expect Regulatory Shortcuts As the 21st Century Cures Act cleared the U.S. Senate last week, many attendees of the annual World Stem Cell Summit took a victory lap. The meeting assembled some of the lawyers, analysts, and activists who have long pushed for reform of how the U.S. Food and Drug Administration handles regenerative medicine. And the behemoth biomedical bill predicted to get a presidential signature this week could allow some stem cell products a faster and more flexible premarket approval process. [ScienceInsider] Editorial Brexit by the Numbers: The Fear of Brain Drain British universities fear losing large swathes of their research staff as the country faces up to Brexit, the split with the European Union. More than 31,000 academics at UK universities are non-British EU citizens, and so may lose their rights to live in the United Kingdom after Brexit. [Nature Trend Watch] Editorial Italian Scientists Won’t Miss Departing Prime Minister Matteo Renzi Italian politics is in turmoil after the resignation of Prime Minister Matteo Renzi — but researchers say that they are not particularly sad to see him go. In his almost three years in charge, Renzi promised improvements for universities and science but failed to raise the status of research in the country, according to scientists who complain that he also directly interfered in academic affairs. [Nature News] Editorial
| |
EVENTSNEW International Society for Stem Cell Research (ISSCR) Annual Meeting 2017 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Scientist – Insulin Secretion (Helmholtz Association) Senior Scientist – Pancreatic Cell Research (STEMCELL Technologies Inc.) Principle Scientist – Translational Development (Celgene Corporation) Postdoctoral Researcher – Cell Biology (Northwestern University) Postdoctoral Researcher – Pancreatic Cancer (Karlsruhe Institute of Technology) Postdoctoral Researcher – Diabetes Research (Karolinska Institutet) Postdoctoral Researcher – Hyperglycemia and the Pancreatic Beta-Cell (University of Oxford) Assistant Professor – Molecular Therapeutics (Dartmouth College / Geisel School of Medicine) Postdoctoral Research Associate – Structural Biology (Arizona State University) Faculty Position – Cancer Immunology (University of New Mexico) Assistant Professor – Cancer Cell Biology (North Dakota State University) Vice President – Pancreatic Cancer Disease Lead (Celgene Corporation) Postdoctoral Research Fellow – Pancreas Cancer (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Pancreatic Cell News Volume 7.49 | Dec 13 2016